English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Dulaglutide is a once‐weekly glucagon‐like peptide‐1 receptor agonist approved for the treatment of type 2 diabetes (T2D). Integrated data from 9 phase  II  and  III  trials in people with  T2D  (N = 6005) were used to evaluate the effects of dulaglutide on estimated glomerular filtration rate ( eGFR  [Chronic Kidney Disease Epidemiology Collaboration]), urine albumin‐to‐creatinine ratio ( UACR ) and kidney adverse events ( AEs ). No significant differences in  eGFR  were observed during treatment for dulaglutide vs placebo, active comparators or insulin glargine (mean ± standard deviation values: dulaglutide vs placebo: 87.8 ± 17.7 vs 88.2 ± 17.9  mL /min/1.73 m 2 ,  P  = .075; dulaglutide vs active comparators: 89.9 ± 16.7 vs 88.8 ± 16.3  mL /min/1.73 m 2 ,  P  = .223; and dulaglutide vs insulin glargine: 85.9 ± 18.2 vs 83.9 ± 18.6  mL /min/1.73 m 2 ,  P  = .423). Lower  UACR  values were observed for dulaglutide vs placebo, active comparators and insulin glargine (at 26 weeks, median [ Q1‐Q3 ] values were: dulaglutide vs placebo: 8.0 [4.4‐20.4] vs 8.0 [4.4‐23.9] mg/g,  P  = .023; dulaglutide vs active comparators: 8.0 [4.4‐21.2] vs 8.9 [4.4‐27.4] mg/g,  P  = .013; and dulaglutide vs insulin glargine: 8.9 [4.4‐29.2] vs 12.4 [5.3‐50.5] mg/g,  P  = .029).  AEs  reflecting potential acute renal failure were 3.4, 1.7 and 7.0 events/1000 patient‐years for dulaglutide, active comparators and placebo, respectively. In conclusion, dulaglutide treatment of clinical trial participants with  T2D  did not affect  eGFR  and slightly decreased albuminuria.

Effects of once‐weekly dulaglutide on kidney function in patients with type 2 diabetes in phase II and III clinical trials